- Home
- MCRB vs JSPR Comparison
MCRB vs JSPR Comparison
Compare MCRB & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- JSPR
- Stock Information
- Founded
- MCRB 2010
- JSPR 2018
- Country
- MCRB United States
- JSPR United States
- Employees
- MCRB N/A
- JSPR N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCRB Health Care
- JSPR Health Care
- Exchange
- MCRB Nasdaq
- JSPR Nasdaq
- Market Cap
- MCRB 103.7M
- JSPR 85.8M
- IPO Year
- MCRB 2015
- JSPR N/A
- Fundamental
- Price
- MCRB $12.09
- JSPR $3.51
- Analyst Decision
- MCRB Hold
- JSPR Buy
- Analyst Count
- MCRB 4
- JSPR 12
- Target Price
- MCRB $73.67
- JSPR $31.67
- AVG Volume (30 Days)
- MCRB 109.0K
- JSPR 1.4M
- Earning Date
- MCRB 08-12-2025
- JSPR 08-12-2025
- Dividend Yield
- MCRB N/A
- JSPR N/A
- EPS Growth
- MCRB N/A
- JSPR N/A
- EPS
- MCRB 8.98
- JSPR N/A
- Revenue
- MCRB N/A
- JSPR N/A
- Revenue This Year
- MCRB N/A
- JSPR N/A
- Revenue Next Year
- MCRB N/A
- JSPR N/A
- P/E Ratio
- MCRB $1.50
- JSPR N/A
- Revenue Growth
- MCRB N/A
- JSPR N/A
- 52 Week Low
- MCRB $6.53
- JSPR $2.27
- 52 Week High
- MCRB $30.60
- JSPR $26.05
- Technical
- Relative Strength Index (RSI)
- MCRB 66.74
- JSPR 37.54
- Support Level
- MCRB $10.67
- JSPR $2.71
- Resistance Level
- MCRB $12.84
- JSPR $4.00
- Average True Range (ATR)
- MCRB 1.09
- JSPR 0.67
- MACD
- MCRB 0.34
- JSPR -0.28
- Stochastic Oscillator
- MCRB 85.98
- JSPR 29.21
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.